{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:28:42Z","timestamp":1792002522576,"version":"4.4.0"},"reference-count":162,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jhep.2024.04.007","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T21:02:55Z","timestamp":1717621375000},"page":"326-344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["EASL position paper on clinical follow-up after HCV cure"],"prefix":"10.1016","volume":"81","author":[{"given":"Thomas","family":"Reiberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabela","family":"Lens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cabibbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Nahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Linda","family":"Zignego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Deterding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Elsharkawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8188-1764","authenticated-orcid":false,"given":"Xavier","family":"Forns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2024.04.007_bib1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1148\/radiol.2020192437","article-title":"Update to the society of radiologists in ultrasound liver elastography consensus statement","volume":"296","author":"Barr","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.jhep.2024.04.007_bib2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","article-title":"Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C","volume":"128","author":"Cast\u00e9ra","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.04.007_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.20506","article-title":"Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C","volume":"41","author":"Ziol","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.04.007_bib4","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1111\/j.1572-0241.2007.01466.x","article-title":"FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy","volume":"102","author":"Shaheen","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2024.04.007_bib5","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.cgh.2007.07.020","article-title":"Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis","volume":"5","author":"Talwalkar","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib6","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1053\/j.gastro.2008.01.034","article-title":"Performance of transient elastography for the staging of liver fibrosis: a meta-analysis","volume":"134","author":"Friedrich-Rust","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.04.007_bib7","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1365-2893.2009.01087.x","article-title":"Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis","volume":"16","author":"Castera","year":"2009","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2024.04.007_bib8","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib9","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.04.007_bib10","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.04.007_bib11","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis \u2013 2021 update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2009.11.008","article-title":"Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C","volume":"52","author":"Castera","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cgh.2008.10.034","article-title":"Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis","volume":"7","author":"Fontana","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib14","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1365-2893.2008.01055.x","article-title":"Changes of non-invasive markers and FibroScan values during HCV treatment","volume":"16","author":"Vergniol","year":"2009","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2024.04.007_bib15","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.3748\/wjg.v17.i41.4581","article-title":"FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus","volume":"17","author":"Patel","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2024.04.007_bib16","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1365-2893.2008.01062.x","article-title":"An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C","volume":"16","author":"Patel","year":"2009","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2024.04.007_bib17","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/jvh.13280","article-title":"Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy\u2014results from the German Hepatitis C-Registry","volume":"27","author":"Knop","year":"2020","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2024.04.007_bib18","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jhep.2022.08.025","article-title":"Non-invasive tests for clinically significant portal hypertension after HCV cure","volume":"77","author":"Semmler","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jhep.2013.03.013","article-title":"The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response","volume":"59","author":"D\u2019Ambrosio","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib20","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1111\/liv.15058","article-title":"Elastography is unable to exclude cirrhosis after sustained virological response in HCV-infected patients with advanced chronic liver disease","volume":"41","author":"Broquetas","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2024.04.007_bib22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib23","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.3748\/wjg.v20.i11.2854","article-title":"Non-invasive diagnosis of liver fibrosis in chronic hepatitis C","volume":"20","author":"Schiavon Lde","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2024.04.007_bib24","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jhep.2006.12.013","article-title":"Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C","volume":"46","author":"Leroy","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib25","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/hep.22859","article-title":"SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C","volume":"49","author":"Sebastiani","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.04.007_bib26","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2893.2006.00736.x","article-title":"Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies","volume":"13","author":"Bourliere","year":"2006","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2024.04.007_bib27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.24654","article-title":"Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive","volume":"55","author":"Boursier","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.04.007_bib28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1365-2036.2009.04062.x","article-title":"Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C","volume":"30","author":"Smith","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2024.04.007_bib29","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/apt.13954","article-title":"Liver fibrosis diagnosis by blood test and elastography in chronic hepatitis C: agreement or combination?","volume":"45","author":"Cales","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2024.04.007_bib30","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.jhep.2020.08.006","article-title":"Hepatic benefits of HCV cure","volume":"73","author":"Calvaruso","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.007_bib31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.04.007_bib32","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/MCG.0b013e318050074f","article-title":"Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography","volume":"42","author":"Masuzaki","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2024.04.007_bib33","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/liv.12118","article-title":"Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients","volume":"33","author":"Wang","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2024.04.007_bib34","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib35","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib36","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.jhep.2014.08.003","article-title":"Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases","volume":"61","author":"Negro","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib37","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib38","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.04.007_bib39","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S2468-1253(23)00443-0","article-title":"Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study","volume":"9","author":"Israelsen","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib40","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1055\/s-0043-112656","article-title":"Interferon-free cure of chronic Hepatitis C is associated with weight gain during long-term follow-up","volume":"55","author":"Schlevogt","year":"2017","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.jhep.2024.04.007_bib41","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1007\/s11606-020-05782-6","article-title":"Excess weight gain after cure of hepatitis C infection with direct-acting antivirals","volume":"35","author":"Do","year":"2020","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jhep.2024.04.007_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9101495","article-title":"Weight gain after interferon-free treatment of chronic hepatitis C-results from the German hepatitis C-registry (DHC-R)","volume":"9","author":"Schlevogt","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jhep.2024.04.007_bib43","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","article-title":"Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis","volume":"133","author":"Ripoll","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.04.007_bib44","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jhep.2009.01.014","article-title":"Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis","volume":"50","author":"Ripoll","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib45","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib46","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon-free therapies ameliorates HCV-in- duced portal hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib47","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/j.gastro.2017.07.016","article-title":"Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis","volume":"153","author":"Lens","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.04.007_bib48","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","article-title":"Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications","volume":"152","author":"Nahon","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.04.007_bib49","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/j.gastro.2016.03.036","article-title":"Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension","volume":"151","author":"Di Marco","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.04.007_bib50","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/apt.13844","article-title":"Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV\/HCV patients with advanced liver disease","volume":"45","author":"Schwabl","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2024.04.007_bib51","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.humpath.2003.08.012","article-title":"Reversibility of hepatitis C virus-related cirrhosis","volume":"35","author":"Pol","year":"2004","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jhep.2024.04.007_bib52","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/jgh3.12779","article-title":"Analysis of the albumin-bilirubin score as an indicator of improved liver function among hepatitis C virus patients with sustained viral response after direct-acting antiviral therapy","volume":"6","author":"Martinez Herreros","year":"2022","journal-title":"JGH Open"},{"key":"10.1016\/j.jhep.2024.04.007_bib53","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2020.11.050","article-title":"Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease","volume":"74","author":"Papatheodoridi","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib54","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00508-012-0190-5","article-title":"Noninvasive screening for liver fibrosis and portal hypertension by transient elastography--a large single center experience","volume":"124","author":"Reiberger","year":"2012","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.jhep.2024.04.007_bib55","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/hep4.1855","article-title":"The value of liver and spleen stiffness for evaluation of portal hypertension in compensated cirrhosis","volume":"6","author":"Reiberger","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2024.04.007_bib56","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib57","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2018.11.053","article-title":"Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy","volume":"156","author":"Thabut","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.04.007_bib58","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2024.04.007_bib59","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/hep.28264","article-title":"Development of hyperdynamic circulation and response to \u03b2-blockers in compensated cirrhosis with portal hypertension","volume":"63","author":"Villanueva","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.04.007_bib60","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1053\/j.gastro.2018.03.022","article-title":"Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection","volume":"154","author":"El-Sherif","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.04.007_bib61","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jhep.2020.11.021","article-title":"Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity","volume":"74","author":"Krassenburg","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib62","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jhep.2020.03.031","article-title":"DAA therapy and long-term hepatic function in advanced\/decompensated cirrhosis: real-world experience from HCV-TARGET cohort","volume":"73","author":"Verna","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib63","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jhep.2022.06.001","article-title":"EASL Clinical Practice Guidelines on the management of hepatic encephalopathy","volume":"77","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib64","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jhep.2020.05.050","article-title":"Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension","volume":"73","author":"Lens","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jhep.2018.02.012","article-title":"The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition","volume":"69","author":"Crespo","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib66","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/hep.28923","article-title":"Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy","volume":"65","author":"Flemming","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.04.007_bib67","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.jhep.2017.08.008","article-title":"Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation","volume":"67","author":"Pascasio","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib68","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study","volume":"65","author":"Belli","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib69","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1016\/j.cgh.2020.09.033","article-title":"In the era of direct-acting antivirals, liver transplant delisting due to clinical improvement for hepatitis C remains infrequent","volume":"19","author":"Bittermann","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib70","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1111\/liv.13878","article-title":"Delisting HCV-infected liver transplant candidates who improved after viral eradication: outcome 2 years after delisting","volume":"38","author":"Perricone","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2024.04.007_bib71","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma","volume":"158","author":"Morgan","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2024.04.007_bib72","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib73","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/hep.32341","article-title":"HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis","volume":"76","author":"Lockart","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.04.007_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2019.03.027","article-title":"Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients","author":"Cabibbo","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib75","article-title":"Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis","author":"Sapena","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.04.007_bib76","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jhep.2021.01.046","article-title":"Antiviral therapy in the palliative setting of HCC (BCLC-B and -C)","volume":"74","author":"Reig","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib77","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased risk for hepatocellular carcinoma persists up to 10 Years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores","volume":"157","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.04.007_bib79","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents","volume":"155","author":"Calvaruso","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.04.007_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2019.01.005","article-title":"Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules","volume":"70","author":"Mari\u00f1o","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib81","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2022.06.057","article-title":"Hepatocellular carcinoma risk declines but remains high enough for screening in the first 7 Years after hepatitis C virus cure with direct-acting antivirals in patients with cirrhosis or high fibrosis-4 score","volume":"163","author":"Kim","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.04.007_bib82","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jhep.2021.11.025","article-title":"HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease","volume":"76","author":"Semmler","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib83","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31588","article-title":"A model based on noninvasive markers predicts very low hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis","author":"Alonso Lopez","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.04.007_bib84","article-title":"Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection","volume":"3","author":"Innes","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2024.04.007_bib85","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jhep.2020.05.052","article-title":"Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status","volume":"73","author":"Audureau","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib86","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jhep.2020.07.025","article-title":"aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis","volume":"73","author":"Fan","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib87","article-title":"A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation","volume":"95","author":"Nishikawa","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jhep.2024.04.007_bib88","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/liv.12516","article-title":"Reappraisal of serum alpha-foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment","volume":"35","author":"Kim","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2024.04.007_bib89","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1111\/jgh.12612","article-title":"Oral antiviral therapy improves the diagnostic accuracy of alpha-fetoprotein levels in patients with chronic hepatitis B","volume":"29","author":"Shim","year":"2014","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib90","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/hep.26739","article-title":"On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir","volume":"59","author":"Wong","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.04.007_bib91","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/jgh.12921","article-title":"Prediction of risk for hepatocellular carcinoma by response of serum \u03b1-fetoprotein to entecavir therapy","volume":"30","author":"Yang","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib92","article-title":"Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis","volume":"4","author":"Nahon","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2024.04.007_bib93","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.26442","article-title":"\u03b1-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C","volume":"58","author":"Asahina","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.04.007_bib94","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.14309\/ajg.0000000000000715","article-title":"Cost-effectiveness of hepatocellular carcinoma surveillance: an assessment of benefits and harms","volume":"115","author":"Parikh","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2024.04.007_bib95","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1053\/j.gastro.2018.07.015","article-title":"Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs","volume":"155","author":"Nahon","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.04.007_bib96","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.04.007_bib97","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.30823","article-title":"Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.04.007_bib98","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.cgh.2018.12.018","article-title":"Cost effectiveness of hepatocellular carcinoma surveillance after a sustained virologic response to therapy in patients with hepatitis C virus infection and advanced fibrosis","volume":"17","author":"Farhang Zangneh","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib100","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.04.007_bib101","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","volume":"67","author":"Chung","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2024.04.007_bib102","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jhep.2011.10.007","article-title":"Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe","volume":"56","author":"Myers","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib103","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1053\/j.gastro.2012.02.017","article-title":"Noninvasive methods to assess liver disease in patients with hepatitis B or C","volume":"142","author":"Castera","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.04.007_bib104","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jhep.2021.11.023","article-title":"Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules","volume":"76","author":"Sanduzzi-Zamparelli","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jhep.2022.01.027","article-title":"Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication","volume":"77","author":"Mueller","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib106","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1016\/S1470-2045(23)00186-9","article-title":"Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept","volume":"24","author":"Vitale","year":"2023","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.007_bib107","first-page":"353","article-title":"Stratification of hepatocellular carcinoma risk following HCV eradication or HBV control","volume":"10","author":"Nahon","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jhep.2024.04.007_bib108","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.jhep.2023.05.005","article-title":"Statistical perspectives on using hepatocellular carcinoma risk models to inform surveillance decisions","volume":"79","author":"Innes","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib109","article-title":"HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a systematic review and meta-analysis","volume":"2022","author":"Singal","year":"2022","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.007_bib110","article-title":"International liver cancer association (ILCA) white paper on hepatocellular carcinoma risk stratification and surveillance","volume":"10","author":"Singal","year":"2023","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.007_bib111","article-title":"Screening of liver cancer with abbreviated magnetic resonance imaging","volume":"10","author":"Ronot","year":"2023","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.007_bib112","article-title":"Magnetic resonance imaging is cost-effective for hepatocellular carcinoma surveillance in high risk patients with cirrhosis","volume":"10","author":"Kim","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.04.007_bib113","first-page":"3","article-title":"Extrahepatic manifestations of chronic hepatitis C virus infection","volume":"3","author":"Cacoub","year":"2016","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.jhep.2024.04.007_bib114","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1056\/NEJMc2106143","article-title":"Extrahepatic manifestations of chronic HCV\u00a0infection","volume":"385","author":"Ferri","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2024.04.007_bib115","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.autrev.2017.03.004","article-title":"International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement","volume":"16","author":"Zignego","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jhep.2024.04.007_bib116","first-page":"1","article-title":"Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia","volume":"00","author":"Gragnani","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.04.007_bib117","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/bjh.17036","article-title":"Direct-acting antiviral agents for hepatitis C virus-mixed cryoglobulinaemia: dissociated virological and haematological responses","volume":"191","author":"Pozzato","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jhep.2024.04.007_bib118","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13075-017-1280-6","article-title":"Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience","volume":"19","author":"Lauletta","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jhep.2024.04.007_bib119","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1097\/MEG.0000000000001239","article-title":"Are direct-acting antivirals safe and effective in hepatitis C virus-cryoglobulinemia? virological, immunological, and clinical data from a real-life experience","volume":"30","author":"Passerini","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib120","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1111\/liv.15002","article-title":"Peripheral neuropathy after viral eradication with direct-acting antivirals in chronic HCV hepatitis: a prospective study","volume":"41","author":"Zanone","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2024.04.007_bib121","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s10875-023-01444-4","article-title":"COVID-19 and mixed cryoglobulinemia syndrome: long-term survey study on the prevalence and outcome, vaccine safety, and immunogenicity","volume":"43","author":"Gragnani","year":"2023","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jhep.2024.04.007_bib122","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1093\/rheumatology\/kew268","article-title":"Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy","volume":"55","author":"Sollima","year":"2016","journal-title":"Rheumatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib123","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/rheumatology\/key157","article-title":"Late relapses of hepatitis C virus-cured mixed cryoglobulinaemia associated with infection or cancer","volume":"57","author":"Visentini","year":"2018","journal-title":"Rheumatol"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.007_bib124","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.gastro.2018.04.024","article-title":"Long-term outcomes of patients with hcv-associated cryoglobulinemic vasculitis after virologic cure","volume":"155","author":"Bonacci","year":"2018","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.007_bib125","first-page":"161","article-title":"Recurrence of mixed cryoglobulinaemia vasculitis following influenza vaccination despite clearance of hepatitis C virus infection","volume":"36","author":"Sollima","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib126","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1136\/annrheumdis-2021-221248","article-title":"Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2","volume":"81","author":"Visentini","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jhep.2024.04.007_bib127","first-page":"787","article-title":"COVID-19 vaccination rate and safety profile in a multicentre Italian population affected by mixed cryoglobulinaemic vasculitis","volume":"41","author":"Vacchi","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib128","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/hep.32281","article-title":"A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort","volume":"76","author":"Kondili","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.04.007_bib129","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/hep.31804","article-title":"Hematological and genetic markers in the rational approach to patients with HCV sustained virological response with or without persisting cryoglobulinemic vasculitis","volume":"74","author":"Gragnani","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.04.007_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102923","article-title":"Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life","volume":"21","author":"Gragnani","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jhep.2024.04.007_bib131","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3851\/IMP3247","article-title":"Expert opinion on the management of renal manifestations of chronic HCV infection","volume":"23","author":"Fabrizi","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2024.04.007_bib132","first-page":"258","article-title":"Hepatitis C virus as a multifaceted disease: a simple and updated approach for extrahepatic manifestations of hepatitis C virus infection","volume":"10","author":"Khattab","year":"2010","journal-title":"Hepat Mon"},{"key":"10.1016\/j.jhep.2024.04.007_bib133","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.dld.2018.08.022","article-title":"Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectio","volume":"50","author":"Minutolo","year":"2018","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2024.04.007_bib134","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.semarthrit.2003.10.001","article-title":"Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients","volume":"33","author":"Ferri","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jhep.2024.04.007_bib135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-018-0009-4","article-title":"Cryoglobulinaemia","volume":"4","author":"Roccatello","year":"2018","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.jhep.2024.04.007_bib136","article-title":"Factors associated with large renal function decline in patients with chronic hepatitis C successfully treated with direct-acting antiviral therapy","volume":"13","author":"Chen","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jhep.2024.04.007_bib1a","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1158\/1055-9965.EPI-06-0308","article-title":"Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies","volume":"15","author":"Dal Maso","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jhep.2024.04.007_bib2a","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1093\/annonc\/mdl131","article-title":"Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy","volume":"17","author":"Visco","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2024.04.007_bib3a","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2016-05-714667","article-title":"Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection","volume":"128","author":"Arcaini","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jhep.2024.04.007_bib4a","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/s41375-019-0687-2","article-title":"Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection","volume":"34","author":"Frigeni","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jhep.2024.04.007_bib5a","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jhep.2014.09.031","article-title":"Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3\/NS4A inhibitor-based treatment. A case report","volume":"62","author":"Rossotti","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib6a","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2014-12-618652","article-title":"Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment","volume":"125","author":"Sultanik","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jhep.2024.04.007_bib7a","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1111\/liv.12897","article-title":"HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents","volume":"35","author":"Carrier","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2024.04.007_bib8a","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1056\/NEJMc1513288","article-title":"Remission of Follicular Lymphoma after Treatment for Hepatitis C Virus Infection","volume":"375","author":"Maciocia","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2024.04.007_bib9a","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jvh.12518","article-title":"The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis","volume":"23","author":"Peveling-Oberhag","year":"2016","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2024.04.007_bib10a","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/bjh.18678","article-title":"Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective \u2018Elderly Project' by the Fondazione Italiana Linfomi","volume":"201","author":"Arcari","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jhep.2024.04.007_bib11a","doi-asserted-by":"crossref","first-page":"ofw223","DOI":"10.1093\/ofid\/ofw223","article-title":"Concurrent Systemic Chemoimmunotherapy and Sofosbuvir-Based Antiviral Treatment in a Hepatitis C Virus-Infected Patient With Diffuse Large B-Cell Lymphoma","volume":"3","author":"Ewers","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jhep.2024.04.007_bib12a","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.14309\/ajg.0000000000000606","article-title":"Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)","volume":"115","author":"Huang","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2024.04.007_bib137","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jhep.2007.11.022","article-title":"Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C","volume":"48","author":"Romero-G\u00f3mez","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib138","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/apt.15102","article-title":"Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes","volume":"49","author":"Li","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2024.04.007_bib139","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/jmv.24954","article-title":"Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents","volume":"90","author":"Ciancio","year":"2018","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhep.2024.04.007_bib140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/life13020534","article-title":"Changes in components of metabolic syndrome after antiviral eradication in hepatitis C virus infection","volume":"13","author":"Trifan","year":"2023","journal-title":"Life"},{"key":"10.1016\/j.jhep.2024.04.007_bib141","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jhep.2018.02.015","article-title":"Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis","volume":"69","author":"Petta","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.007_bib142","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jcv.2009.10.005","article-title":"Hepatitis C virus RNA localization in human carotid plaques","volume":"47","author":"Boddi","year":"2010","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jhep.2024.04.007_bib143","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1111\/jvh.13614","article-title":"Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland","volume":"28","author":"Caven","year":"2021","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2024.04.007_bib144","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/jvh.13707","article-title":"Determining the frequency and characteristics of hepatitis C reinfections in North East England","volume":"29","author":"Askar","year":"2022","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2024.04.007_bib145","article-title":"HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates","volume":"4","author":"Lens","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2024.04.007_bib146","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/jvh.13240","article-title":"High rate of hepatitis C reinfection following antiviral treatment in the North East England Prisons","volume":"27","author":"Bhandari","year":"2020","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2024.04.007_bib147","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/cid\/ciac246","article-title":"Hepatitis C virus reinfection following direct-acting antiviral treatment in the prison setting: the SToP-C study","volume":"75","author":"Carson","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2024.04.007_bib148","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/cid\/ciaa645","article-title":"Incidence of HCV reinfection among HIV-positive MSM and its association with sexual risk behavior: a longitudinal analysis","volume":"73","author":"Newsum","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2024.04.007_bib149","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1111\/jvh.13378","article-title":"Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH)","volume":"27","author":"Mora","year":"2020","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2024.04.007_bib150","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jcv.2009.04.007","article-title":"Holiday haemodialysis and imported hepatitis C virus infection: a series of sixteen cases in two large haemodialysis units","volume":"45","author":"Bhattacharya","year":"2009","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jhep.2024.04.007_bib151","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/apt.16697","article-title":"Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment","volume":"55","author":"Liu","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2024.04.007_bib152","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.kint.2022.07.012","article-title":"Executive summary of the KDIGO 2022 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease","volume":"102","author":"Martin","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.jhep.2024.04.007_bib153","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28544","article-title":"Usefulness of dried blood spot samples for monitoring hepatitis {C} treatment outcome and reinfection among people who inject drugs in a test-and-treat program","volume":"95","author":"Not","year":"2023","journal-title":"J Med Virol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824002757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824002757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:59:32Z","timestamp":1773457172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827824002757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":162,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0168827824002757"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2024.04.007","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EASL position paper on clinical follow-up after HCV cure","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}